Truist Securities Maintains Buy on Dianthus Therapeutics, Raises Price Target to $128
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.
Truist Securities analyst Danielle Brill maintains Dianthus Therapeutics (NASDAQ:DNTH) with a Buy and raises the price target from $110 to $128.